ImExHS Ltd

ImExHS operates with a current ratio of 1.73, indicating moderate liquidity, and a debt-to-equity ratio of 0.04, suggesting a conservative capital structure. The company's free cash flow is negative at -1,906,910 AUD, and its operating cash flow is 564,710 AUD, reflecting a cash outflow from operations. The company's profitability is weak, with a return on equity of -18.16% and a return on assets of -12.15%. These figures are below the typical performance metrics for the healthcare technology industry, indicating a need for operational improvements to enhance returns. ImExHS generates revenue from its SaaS solutions and diagnostic services, with a focus on cloud-based systems such as AQUILA, ALULA, and ANTEROS. The company's geographic exposure is concentrated in Colombia, the United States, and Australia, with no detailed breakdown of revenue by region provided in the available data. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the negative operating income of -2,626,960 AUD and net loss of -2,882,310 AUD suggest challenges in achieving profitability. The capital expenditure of -1,242,590 AUD indicates ongoing investment in infrastructure. ImExHS faces moderate liquidity risk, as noted in the risk assessment, and the company has a low dilution risk. The negative net cash position after subtracting total debt is a key flag, but the company has not issued additional shares recently, and there are no indications of near-term dilution. Recent events include the company's continued focus on developing AI tools using its radiology services and medical images. The company's recent financial performance and operational cash flow suggest a need for strategic adjustments to improve financial health.